WO2007051201A3 - Muteines des sites de glycosylation de tlr3 et leurs procedes d'utilisation - Google Patents

Muteines des sites de glycosylation de tlr3 et leurs procedes d'utilisation Download PDF

Info

Publication number
WO2007051201A3
WO2007051201A3 PCT/US2006/060357 US2006060357W WO2007051201A3 WO 2007051201 A3 WO2007051201 A3 WO 2007051201A3 US 2006060357 W US2006060357 W US 2006060357W WO 2007051201 A3 WO2007051201 A3 WO 2007051201A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
glycosylation site
muteins
tlr3
site muteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/060357
Other languages
English (en)
Other versions
WO2007051201A2 (fr
Inventor
Karen E Duffy
Mark Cunningham
M Lamine Mbow
Robert T Sarisky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to EP06846186A priority Critical patent/EP1945657B1/fr
Priority to PL06846186T priority patent/PL1945657T3/pl
Priority to ES06846186T priority patent/ES2375999T3/es
Priority to DK06846186.2T priority patent/DK1945657T3/da
Priority to JP2008538208A priority patent/JP2009515511A/ja
Priority to AT06846186T priority patent/ATE530562T1/de
Publication of WO2007051201A2 publication Critical patent/WO2007051201A2/fr
Publication of WO2007051201A3 publication Critical patent/WO2007051201A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des mutéines des sites de glycosylation de TLR3, à des acides nucléiques codant lesdites mutéines, et à des procédés permettant de moduler l'activité de TLR3 dans une cellule.
PCT/US2006/060357 2005-10-28 2006-10-30 Muteines des sites de glycosylation de tlr3 et leurs procedes d'utilisation Ceased WO2007051201A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP06846186A EP1945657B1 (fr) 2005-10-28 2006-10-30 Mutéines des sites de glycosylation de Tlr3 et leurs procédés d'utilisation
PL06846186T PL1945657T3 (pl) 2005-10-28 2006-10-30 Muteiny Tlr3 zmienione w miejscu glikozylacji i ich zastosowanie
ES06846186T ES2375999T3 (es) 2005-10-28 2006-10-30 Mute�?nas de sitio de glucosilación tlr3 y procedimientos de uso.
DK06846186.2T DK1945657T3 (da) 2005-10-28 2006-10-30 TLR3-glycosyleringsstedsmuteiner samt fremgangsmåde til deres anvendelse
JP2008538208A JP2009515511A (ja) 2005-10-28 2006-10-30 Ｔｌｒ３のグリコシル化部位ムテインおよび使用方法
AT06846186T ATE530562T1 (de) 2005-10-28 2006-10-30 Tlr3-glycosylierungsstandortmuteine und verwendungsverfahren dafür

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73110505P 2005-10-28 2005-10-28
US60/731,105 2005-10-28

Publications (2)

Publication Number Publication Date
WO2007051201A2 WO2007051201A2 (fr) 2007-05-03
WO2007051201A3 true WO2007051201A3 (fr) 2008-02-14

Family

ID=37968693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/060357 Ceased WO2007051201A2 (fr) 2005-10-28 2006-10-30 Muteines des sites de glycosylation de tlr3 et leurs procedes d'utilisation

Country Status (11)

Country Link
US (1) US20070203064A1 (fr)
EP (1) EP1945657B1 (fr)
JP (1) JP2009515511A (fr)
AT (1) ATE530562T1 (fr)
CY (1) CY1112512T1 (fr)
DK (1) DK1945657T3 (fr)
ES (1) ES2375999T3 (fr)
PL (1) PL1945657T3 (fr)
PT (1) PT1945657E (fr)
SI (1) SI1945657T1 (fr)
WO (1) WO2007051201A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2550264T3 (es) * 2008-10-02 2015-11-05 Janssen Biotech, Inc. Métodos para suprimir la actividad de receptores tipo Toll
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
US20220170042A1 (en) * 2020-11-27 2022-06-02 Wyvern Pharmaceuticals Inc. Compositions and methods for regulating production of a precursor protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243540A (en) * 1991-04-03 1993-09-07 The United States Of America As Represented By The Secretary Of The Army Computer-driven amino acid indexer for peptide synthesis
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5243540A (en) * 1991-04-03 1993-09-07 The United States Of America As Represented By The Secretary Of The Army Computer-driven amino acid indexer for peptide synthesis
US6900016B1 (en) * 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof

Also Published As

Publication number Publication date
DK1945657T3 (da) 2012-02-06
ES2375999T3 (es) 2012-03-08
EP1945657B1 (fr) 2011-10-26
PT1945657E (pt) 2012-02-02
EP1945657A2 (fr) 2008-07-23
US20070203064A1 (en) 2007-08-30
CY1112512T1 (el) 2015-12-09
SI1945657T1 (sl) 2012-03-30
JP2009515511A (ja) 2009-04-16
PL1945657T3 (pl) 2012-03-30
ATE530562T1 (de) 2011-11-15
EP1945657A4 (fr) 2009-06-03
WO2007051201A2 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
WO2005103076A3 (fr) Variants d'erythropoietine
IL179942A0 (en) Electrochemical methods, devices, and structures
CA115125S (en) Electrode array
WO2009051717A3 (fr) Variantes du facteur ix humain qui présentent une demi-vie prolongée
WO2007073484A3 (fr) Procedes et systemes de conduite d’operations de recherche
CA107740S (en) Toy building element
WO2006068972A3 (fr) Dispositifs d'ingenierie tissulaire destines a reparer et a regenerer des tissus
WO2003083054A9 (fr) Amylases, acides nucleiques les codant et procedes de fabrication et d'utilisation correspondants
PL1748954T3 (pl) Fosfolipazy, kodujące je kwasy nukleinowe i sposoby ich wytwarzania i stosowania
EP1754234A4 (fr) Piles a combustible a faible teneur en platine et procede de fabrication desdites piles
PL1926813T3 (pl) Populacje komórkowe mające aktywność immunoregulatorową, sposób izolacji i zastosowania
NO20053357D0 (no) Dyrkingsmedium, dyrkingsmetode og de oppnadde myoblaster og deres anvendelse.
WO2005108428A3 (fr) Variants d'epissage de cd40 et leurs utilisations
PL1819214T3 (pl) Szklarnia, układ sterowania klimatem szklarni oraz sposób sterowania klimatem szklarni
WO2006029389A9 (fr) Enzymes de transformation de tryptophanes, acides nucleiques codant pour de telles enzymes et leurs procedes de fabrication et d'utilisation
CY1112512T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΕΣ ΠΡΩΤΕΪΝΕΣ ΘΕΣΗΣ ΓΛΥΚΟΖΥΛΙΩΣΗΣ ΤIr3 ΚΑΙ ΜΕΘΟΔΟΙ ΧΡΗΣΗΣ
IL172416A0 (en) Modified human acid sphingomyelinase having increased activity, and methods for making the same
CA109415S (en) Printer
FI20055013A0 (fi) Tiedonsiirtomenetelmä tiedonsiirtojärjestelmässä, kontrolleri ja tiedonsiirtopäätelaite
WO2006120192A3 (fr) Creation activee par micro-ondes d'especes catalytiques
PT1763515E (pt) Ácidos 4-trifluorometoxifenoxibenzeno-4¿-sulfónicos, processo para a sua preparação e utilização em medicamentos
AU2003296454A1 (en) Increasing skin cell renewal with water-soluble vitamin e
HK1115817A (en) Concentrated protein lyophilates, methods, and uses
HK1104766A (en) Modulating phosphatase activity in cardiac cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2008538208

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006846186

Country of ref document: EP